First multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing to evaluate reproducibility and concordance of this new protocol.
All HIV-1 drug resistance mutations identified by population sequencing were also identified by 454 ultra-deep pyrosequencing.
Minority HIV-1 drug resistance mutations were only detected by 454 ultra-deep pyrosequencing.
454 ultra-deep pyrosequencing provided highly concordant results together with excellent cross-site correlation.